𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver transplantation for primary and secondary hepatic apudomas

✍ Scribed by J. C. Arnold; J. G. O'Grady; G. L. Bird; R. Y. Calne; Dr. R. Williams


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
264 KB
Volume
76
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Is hepatic transplantation justified for
✍ Robert A. Fisher; Daniel G. Maluf; Luke Wolfe; Bridgette Williams; Adrian Cotter πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 212 KB

## Abstract A concise, yet objective overview of Hepatocellular Carcinoma (HCC) treatment in 2006 with an intent to transplant is presented. The most significant variables impacting on the use of hepatic transplantation as therapy for primary liver cancer are developed under the headings of: Stagin

Liver transplantation for giant hepatic
✍ Parsia A. Vagefi; Helge Eilers; Annie Hiniker; Chris E. Freise πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 148 KB

A 57-year-old gentleman with a past medical history significant for Hodgkin's lymphoma in 1977 (which required splenectomy, radiation therapy, and chemotherapy) was incidentally found to have a large left lobe liver mass in July 2008 while he was undergoing computed tomography imaging for presumed n

Development of autoimmune hepatitis foll
✍ David E. Jones; Oliver F. James; Bernard Portmann; Alastair D. Burt; Roger Willi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 456 KB πŸ‘ 2 views

Two patients undergoing liver transplantation for classical end-stage primary biliary cirrhosis (PBC) are described, who went on to develop de novo autoimmune hepatitis (AIH) in the transplanted liver. The presentation, in both instances, was with malaise and lethargy. Markedly elevated serum transa

Liver transplantation for hepatitis B: E
✍ Schiff, Eugene R. πŸ“‚ Article πŸ“… 1995 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 195 KB

iver transplantation for patients with hepatitis B infection is rapidly changing. The initial L experience of dismal graft and patient survival rates has resulted in denial of reimbursement by many private and federal insurance carriers. This has been tempered by better selection of candidates and t